International prevalence and risk factors evaluation for drug-resistant Streptococcus pneumoniae pneumonia

Stefano Aliberti, Grayden S. Cook, Bettina L. Babu, Luis F. Reyes, Alejandro H. Rodriguez, Francisco Sanz, Nilam J. Soni, Antonio R Anzueto, Paola Faverio, Ricardo Franco Sadud, Irfan Muhammad, Cristina Prat, Ester Vendrell, Joao Neves, Evangelos Kaimakamis, Andrew Feneley, Rajesh Swarnakar, Fabio Franzetti, Manuela Carugati, Manuela Morosi & 2 others Elisa Monge, Marcos Restrepo

Research output: Contribution to journalArticle

Abstract

Objective: Streptococcus pneumoniae is the most frequent bacterial pathogen isolated in subjects with Community-acquired pneumonia (CAP) worldwide. Limited data are available regarding the current global burden and risk factors associated with drug-resistant Streptococcus pneumoniae (DRSP) in CAP subjects. We assessed the multinational prevalence and risk factors for DRSP-CAP in a multinational point-prevalence study. Design: The prevalence of DRSP-CAP was assessed by identification of DRSP in blood or respiratory samples among adults hospitalized with CAP in 54 countries. Prevalence and risk factors were compared among subjects that had microbiological testing and antibiotic susceptibility data. Multivariate logistic regressions were used to identify risk factors independently associated with DRSP-CAP. Results: 3,193 subjects were included in the study. The global prevalence of DRSP-CAP was 1.3% and continental prevalence rates were 7.0% in Africa, 1.2% in Asia, and 1.0% in South America, Europe, and North America, respectively. Macrolide resistance was most frequently identified in subjects with DRSP-CAP (0.6%) followed by penicillin resistance (0.5%). Subjects in Africa were more likely to have DRSP-CAP (OR: 7.6; 95%CI: 3.34-15.35, p<0.001) when compared to centres representing other continents. Conclusions: This multinational point-prevalence study found a low global prevalence of DRSP-CAP that may impact guideline development and antimicrobial policies.

Original languageEnglish (US)
JournalJournal of Infection
DOIs
StatePublished - Jan 1 2019

Fingerprint

Drug Evaluation
Streptococcus pneumoniae
Pneumonia
Pharmaceutical Preparations
Cross-Sectional Studies
Penicillin Resistance
South America
Policy Making
Macrolides
North America
Logistic Models
Guidelines
Anti-Bacterial Agents

Keywords

  • Global burden of disease
  • Microbial drug resistant
  • Pneumococcal infection
  • Pneumonia

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

International prevalence and risk factors evaluation for drug-resistant Streptococcus pneumoniae pneumonia. / Aliberti, Stefano; Cook, Grayden S.; Babu, Bettina L.; Reyes, Luis F.; H. Rodriguez, Alejandro; Sanz, Francisco; Soni, Nilam J.; Anzueto, Antonio R; Faverio, Paola; Sadud, Ricardo Franco; Muhammad, Irfan; Prat, Cristina; Vendrell, Ester; Neves, Joao; Kaimakamis, Evangelos; Feneley, Andrew; Swarnakar, Rajesh; Franzetti, Fabio; Carugati, Manuela; Morosi, Manuela; Monge, Elisa; Restrepo, Marcos.

In: Journal of Infection, 01.01.2019.

Research output: Contribution to journalArticle

Aliberti, S, Cook, GS, Babu, BL, Reyes, LF, H. Rodriguez, A, Sanz, F, Soni, NJ, Anzueto, AR, Faverio, P, Sadud, RF, Muhammad, I, Prat, C, Vendrell, E, Neves, J, Kaimakamis, E, Feneley, A, Swarnakar, R, Franzetti, F, Carugati, M, Morosi, M, Monge, E & Restrepo, M 2019, 'International prevalence and risk factors evaluation for drug-resistant Streptococcus pneumoniae pneumonia', Journal of Infection. https://doi.org/10.1016/j.jinf.2019.07.004
Aliberti, Stefano ; Cook, Grayden S. ; Babu, Bettina L. ; Reyes, Luis F. ; H. Rodriguez, Alejandro ; Sanz, Francisco ; Soni, Nilam J. ; Anzueto, Antonio R ; Faverio, Paola ; Sadud, Ricardo Franco ; Muhammad, Irfan ; Prat, Cristina ; Vendrell, Ester ; Neves, Joao ; Kaimakamis, Evangelos ; Feneley, Andrew ; Swarnakar, Rajesh ; Franzetti, Fabio ; Carugati, Manuela ; Morosi, Manuela ; Monge, Elisa ; Restrepo, Marcos. / International prevalence and risk factors evaluation for drug-resistant Streptococcus pneumoniae pneumonia. In: Journal of Infection. 2019.
@article{8787bb26ff9f4538a245ceec0fd53c7f,
title = "International prevalence and risk factors evaluation for drug-resistant Streptococcus pneumoniae pneumonia",
abstract = "Objective: Streptococcus pneumoniae is the most frequent bacterial pathogen isolated in subjects with Community-acquired pneumonia (CAP) worldwide. Limited data are available regarding the current global burden and risk factors associated with drug-resistant Streptococcus pneumoniae (DRSP) in CAP subjects. We assessed the multinational prevalence and risk factors for DRSP-CAP in a multinational point-prevalence study. Design: The prevalence of DRSP-CAP was assessed by identification of DRSP in blood or respiratory samples among adults hospitalized with CAP in 54 countries. Prevalence and risk factors were compared among subjects that had microbiological testing and antibiotic susceptibility data. Multivariate logistic regressions were used to identify risk factors independently associated with DRSP-CAP. Results: 3,193 subjects were included in the study. The global prevalence of DRSP-CAP was 1.3{\%} and continental prevalence rates were 7.0{\%} in Africa, 1.2{\%} in Asia, and 1.0{\%} in South America, Europe, and North America, respectively. Macrolide resistance was most frequently identified in subjects with DRSP-CAP (0.6{\%}) followed by penicillin resistance (0.5{\%}). Subjects in Africa were more likely to have DRSP-CAP (OR: 7.6; 95{\%}CI: 3.34-15.35, p<0.001) when compared to centres representing other continents. Conclusions: This multinational point-prevalence study found a low global prevalence of DRSP-CAP that may impact guideline development and antimicrobial policies.",
keywords = "Global burden of disease, Microbial drug resistant, Pneumococcal infection, Pneumonia",
author = "Stefano Aliberti and Cook, {Grayden S.} and Babu, {Bettina L.} and Reyes, {Luis F.} and {H. Rodriguez}, Alejandro and Francisco Sanz and Soni, {Nilam J.} and Anzueto, {Antonio R} and Paola Faverio and Sadud, {Ricardo Franco} and Irfan Muhammad and Cristina Prat and Ester Vendrell and Joao Neves and Evangelos Kaimakamis and Andrew Feneley and Rajesh Swarnakar and Fabio Franzetti and Manuela Carugati and Manuela Morosi and Elisa Monge and Marcos Restrepo",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.jinf.2019.07.004",
language = "English (US)",
journal = "Journal of Infection",
issn = "0163-4453",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - International prevalence and risk factors evaluation for drug-resistant Streptococcus pneumoniae pneumonia

AU - Aliberti, Stefano

AU - Cook, Grayden S.

AU - Babu, Bettina L.

AU - Reyes, Luis F.

AU - H. Rodriguez, Alejandro

AU - Sanz, Francisco

AU - Soni, Nilam J.

AU - Anzueto, Antonio R

AU - Faverio, Paola

AU - Sadud, Ricardo Franco

AU - Muhammad, Irfan

AU - Prat, Cristina

AU - Vendrell, Ester

AU - Neves, Joao

AU - Kaimakamis, Evangelos

AU - Feneley, Andrew

AU - Swarnakar, Rajesh

AU - Franzetti, Fabio

AU - Carugati, Manuela

AU - Morosi, Manuela

AU - Monge, Elisa

AU - Restrepo, Marcos

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objective: Streptococcus pneumoniae is the most frequent bacterial pathogen isolated in subjects with Community-acquired pneumonia (CAP) worldwide. Limited data are available regarding the current global burden and risk factors associated with drug-resistant Streptococcus pneumoniae (DRSP) in CAP subjects. We assessed the multinational prevalence and risk factors for DRSP-CAP in a multinational point-prevalence study. Design: The prevalence of DRSP-CAP was assessed by identification of DRSP in blood or respiratory samples among adults hospitalized with CAP in 54 countries. Prevalence and risk factors were compared among subjects that had microbiological testing and antibiotic susceptibility data. Multivariate logistic regressions were used to identify risk factors independently associated with DRSP-CAP. Results: 3,193 subjects were included in the study. The global prevalence of DRSP-CAP was 1.3% and continental prevalence rates were 7.0% in Africa, 1.2% in Asia, and 1.0% in South America, Europe, and North America, respectively. Macrolide resistance was most frequently identified in subjects with DRSP-CAP (0.6%) followed by penicillin resistance (0.5%). Subjects in Africa were more likely to have DRSP-CAP (OR: 7.6; 95%CI: 3.34-15.35, p<0.001) when compared to centres representing other continents. Conclusions: This multinational point-prevalence study found a low global prevalence of DRSP-CAP that may impact guideline development and antimicrobial policies.

AB - Objective: Streptococcus pneumoniae is the most frequent bacterial pathogen isolated in subjects with Community-acquired pneumonia (CAP) worldwide. Limited data are available regarding the current global burden and risk factors associated with drug-resistant Streptococcus pneumoniae (DRSP) in CAP subjects. We assessed the multinational prevalence and risk factors for DRSP-CAP in a multinational point-prevalence study. Design: The prevalence of DRSP-CAP was assessed by identification of DRSP in blood or respiratory samples among adults hospitalized with CAP in 54 countries. Prevalence and risk factors were compared among subjects that had microbiological testing and antibiotic susceptibility data. Multivariate logistic regressions were used to identify risk factors independently associated with DRSP-CAP. Results: 3,193 subjects were included in the study. The global prevalence of DRSP-CAP was 1.3% and continental prevalence rates were 7.0% in Africa, 1.2% in Asia, and 1.0% in South America, Europe, and North America, respectively. Macrolide resistance was most frequently identified in subjects with DRSP-CAP (0.6%) followed by penicillin resistance (0.5%). Subjects in Africa were more likely to have DRSP-CAP (OR: 7.6; 95%CI: 3.34-15.35, p<0.001) when compared to centres representing other continents. Conclusions: This multinational point-prevalence study found a low global prevalence of DRSP-CAP that may impact guideline development and antimicrobial policies.

KW - Global burden of disease

KW - Microbial drug resistant

KW - Pneumococcal infection

KW - Pneumonia

UR - http://www.scopus.com/inward/record.url?scp=85069669834&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069669834&partnerID=8YFLogxK

U2 - 10.1016/j.jinf.2019.07.004

DO - 10.1016/j.jinf.2019.07.004

M3 - Article

JO - Journal of Infection

JF - Journal of Infection

SN - 0163-4453

ER -